达格列净在因COVID-19住院的心血管代谢风险患者中的应用(DARE-19):一项随机双盲安慰剂对照3期试验
DARE-19试验纳入1250例因COVID-19住院且至少有一种心血管代谢风险因素的患者,随机接受达格列净10mg每日一次或安慰剂治疗30天。
要点
- 达格列净未显著降低COVID-19住院患者器官功能障碍或死亡风险。
- 达格列净未显著改善临床恢复,但耐受性良好。
核心结论
- 在因COVID-19住院且有心血管代谢风险因素的患者中,达格列净治疗未显著降低器官功能障碍或死亡风险,也未显著改善临床恢复,但耐受性良好。
研究设计与样本
- DARE-19为随机、双盲、安慰剂对照3期试验,纳入1250例因COVID-19住院且至少有一种心血管代谢风险因素的患者,1:1随机接受达格列净10mg每日一次或安慰剂治疗30天。
临床怎么用
- 对于因COVID-19住院且合并心血管代谢风险因素的患者,达格列净未显示显著器官保护或促进恢复获益,但耐受性良好,临床决策需个体化权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. METHODS: DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients critically ill at screening were excluded. Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days. Dual primary outcomes were assessed in the intention-to-treat population: the outcome of prevention (time to new or worsened organ dysfunction or death), and the hierarchial composite outcome of recovery (change in clinical status by day 30). Safety outcomes, in patients who received at least one study medication dose, included serious adverse events, adverse events leading to discontinuation, and adverse events of interest. This study is registered with ClinicalTrials.gov, NCT04350593. FINDINGS: Between April 22, 2020 and Jan 1, 2021, 1250 patients were randomly assigned with 625 in each group. The primary composite outcome of prevention showed organ dysfunction or death occurred in 70 patients (11·2%) in the dapagliflozin group, and 86 (13·8%) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·58-1·10; p=0·17). For the primary outcome of recovery, 547 patients (87·5%) in the dapagliflozin group and 532 (85·1%) in the placebo group showed clinical status improvement, although this was not statistically significant (win ratio 1·09, 95% CI 0·97-1·22; p=0·14). There were 41 deaths (6·6%) in the dapagliflozin group, and 54 (8·6%) in the placebo group (HR 0·77, 95% CI 0·52-1·16). Serious adverse events were reported in 65 (10·6%) of 613 patients treated with dapagliflozin and in 82 (13·3%) of 616 patients given the placebo. INTERPRETATION: In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. FUNDING: AstraZeneca.
引用
- Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021. PMID: 34302745. doi:10.1016/S2213-8587(21)00180-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。